GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (NAS:RVNC) » Definitions » Days Inventory

Revance Therapeutics (Revance Therapeutics) Days Inventory

: 239.70 (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

Days Inventory is also known as Days Sales of Inventory (DSI). Revance Therapeutics's Average Total Inventories for the three months ended in Dec. 2023 was $45.9 Mil. Revance Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $17.5 Mil. Hence, Revance Therapeutics's Days Inventory for the three months ended in Dec. 2023 was 239.70.

The historical rank and industry rank for Revance Therapeutics's Days Inventory or its related term are showing as below:

RVNC' s Days Inventory Range Over the Past 10 Years
Min: 100.59   Med: 140.9   Max: 449.73
Current: 169.18

During the past 13 years, Revance Therapeutics's highest Days Inventory was 449.73. The lowest was 100.59. And the median was 140.90.

RVNC's Days Inventory is ranked better than
54.08% of 649 companies
in the Biotechnology industry
Industry Median: 191.36 vs RVNC: 169.18

Revance Therapeutics's Days Inventory increased from Dec. 2022 (68.88) to Dec. 2023 (239.70). It might indicate that Revance Therapeutics's sales slowed down.

Warning Sign:

If a company builds up inventory, it may mean it is having difficulties selling its goods.

Inventory Turnover measures how fast the company turns over its inventory within a year. Revance Therapeutics's Inventory Turnover for the three months ended in Dec. 2023 was 0.38.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Revance Therapeutics's Inventory-to-Revenue for the three months ended in Dec. 2023 was 0.66.


Revance Therapeutics Days Inventory Historical Data

The historical data trend for Revance Therapeutics's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Inventory
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 449.73 124.97 100.59 156.83

Revance Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Inventory Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.88 130.07 133.24 189.57 239.70

Competitive Comparison

For the Biotechnology subindustry, Revance Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revance Therapeutics Days Inventory Distribution

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Days Inventory distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's Days Inventory falls into.



Revance Therapeutics Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Revance Therapeutics's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

Days Inventory (A: Dec. 2023 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (18.325 + 45.579) / 2 ) / 74.363*365
=31.952 / 74.363*365
=156.83

Revance Therapeutics's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:

Days Inventory (Q: Dec. 2023 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (Q: Sep. 2023 ) + Total Inventories (Q: Dec. 2023 )) / count ) / Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=( (46.214 + 45.579) / 2 ) / 17.472*365 / 4
=45.8965 / 17.472*365 / 4
=239.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revance Therapeutics  (NAS:RVNC) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Revance Therapeutics's Inventory Turnover for the three months ended in Dec. 2023 is calculated as

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Revance Therapeutics's Inventory to Revenue for the three months ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.


Revance Therapeutics Days Inventory Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Revance Therapeutics (Revance Therapeutics) Business Description

Traded in Other Exchanges
Address
1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Executives
Dwight Moxie officer: SVP, GC & Secretary 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Mark J Foley director ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Tobin Schilke officer: Chief Financial Officer 7000 SHORELINE COURT, #371, SOUTH SAN FRANCISCO CA 94080
Carey Oconnor Kolaja director C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, SUITE 1001, NASHVILLE TN 37203
Dustin S Sjuts officer: President 7555 GATEWAY BLVD, NEWARK CA 94560
Vlad Coric director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Aubrey Rankin director C/O REVANCE THERAPEUTICS, INC, 7555 GATEWAY BLVD, NEWARK CA 94560
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Olivia C Ware director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Jill Beraud director C/O LEVI STRAUSS & CO., 1155 BATTERY STREET, SAN FRANCISCO CA 94111
L Daniel Browne director, officer: CEO and President 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Cyril Allouche officer: Principal Financial Officer 7555 GATEWAY BLVD., NEWARK CA 94560
Lauren P Silvernail officer: CFO, Seretary & EVP Corp Dev. 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Caryn Gordon Mcdowell officer: SVP, GC & Secretary 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080